NCT06738732View on ClinicalTrials.gov

CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Lennox-Gastaut Syndrome (LGS)Dravet Syndrome (DS)
Interventions
DRUG

CBD: GT4 Transdermal Delivery System

CBD: GT4 Transdermal Delivery System

Trial Locations (1)

02115

Boston Childrens' Hospital, Boston

Sponsors

Collaborators (1)

A-Synaptic
All Listed Sponsors
collaborator

A-Synaptic

UNKNOWN

lead

Alexander Rotenberg

OTHER

NCT06738732 - CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome | Biotech Hunter | Biotech Hunter